Cargando…
Azithromycin for mild-to-moderate COVID-19 – Authors' reply
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428487/ https://www.ncbi.nlm.nih.gov/pubmed/34509195 http://dx.doi.org/10.1016/S2213-2600(21)00376-3 |
| _version_ | 1783750388886798336 |
|---|---|
| author | Hinks, Timothy S C |
| author_facet | Hinks, Timothy S C |
| author_sort | Hinks, Timothy S C |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8428487 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84284872021-09-10 Azithromycin for mild-to-moderate COVID-19 – Authors' reply Hinks, Timothy S C Lancet Respir Med Correspondence Elsevier Ltd. 2021-10 2021-09-09 /pmc/articles/PMC8428487/ /pubmed/34509195 http://dx.doi.org/10.1016/S2213-2600(21)00376-3 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Hinks, Timothy S C Azithromycin for mild-to-moderate COVID-19 – Authors' reply |
| title | Azithromycin for mild-to-moderate COVID-19 – Authors' reply |
| title_full | Azithromycin for mild-to-moderate COVID-19 – Authors' reply |
| title_fullStr | Azithromycin for mild-to-moderate COVID-19 – Authors' reply |
| title_full_unstemmed | Azithromycin for mild-to-moderate COVID-19 – Authors' reply |
| title_short | Azithromycin for mild-to-moderate COVID-19 – Authors' reply |
| title_sort | azithromycin for mild-to-moderate covid-19 – authors' reply |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428487/ https://www.ncbi.nlm.nih.gov/pubmed/34509195 http://dx.doi.org/10.1016/S2213-2600(21)00376-3 |
| work_keys_str_mv | AT hinkstimothysc azithromycinformildtomoderatecovid19authorsreply AT azithromycinformildtomoderatecovid19authorsreply |